Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF.

Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ.

Alzheimers Dement. 2013 Mar;9(2):99-112. doi: 10.1016/j.jalz.2012.11.005. Epub 2013 Jan 30.

2.

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.

Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T, Maxwell JW, Hatcher NG, Haugabook SJ, Wu G, Howell BJ, Renger JJ, Shughrue PJ, McCampbell A.

J Neurosci. 2014 Feb 19;34(8):2884-97. doi: 10.1523/JNEUROSCI.1675-13.2014.

3.

Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue.

Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, Verbeek MM.

Anal Biochem. 2013 Feb 15;433(2):112-20. doi: 10.1016/j.ab.2012.09.014. Epub 2012 Sep 26.

PMID:
23022042
4.

A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.

Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ.

Arch Neurol. 2009 Feb;66(2):190-9. doi: 10.1001/archneurol.2008.565.

5.

Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.

Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J.

J Alzheimers Dis. 2015;43(1):183-91. doi: 10.3233/JAD-140771.

PMID:
25079805
6.

Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.

Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, Verbeek MM, Teunissen CE, Veerhuis R.

J Alzheimers Dis. 2015;45(1):35-43. doi: 10.3233/JAD-142136.

PMID:
25547634
7.

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.

JAMA. 2003 Apr 23-30;289(16):2094-103. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
12709467
8.

The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.

Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, Söderberg L, Spens E, Sahlin C, Waara ER, Satlin A, Gellerfors P, Osswald G, Lannfelt L.

J Alzheimers Dis. 2015;43(2):575-88. doi: 10.3233/JAD-140741.

PMID:
25096615
9.

Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.

Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H.

J Alzheimers Dis. 2012;29(1):171-6. doi: 10.3233/JAD-2012-111361.

PMID:
22214781
10.

Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF.

PLoS One. 2013 Oct 7;8(10):e76523. doi: 10.1371/journal.pone.0076523. eCollection 2013.

11.

Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.

Fortea J, Sala-Llonch R, Bartrés-Faz D, Lladó A, Solé-Padullés C, Bosch B, Antonell A, Olives J, Sanchez-Valle R, Molinuevo JL, Rami L.

Biol Psychiatry. 2011 Jul 15;70(2):183-90. doi: 10.1016/j.biopsych.2011.02.017. Epub 2011 Apr 23.

PMID:
21514924
12.

High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.

Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M.

FASEB J. 2010 Aug;24(8):2716-26. doi: 10.1096/fj.09-150359. Epub 2010 Mar 25.

PMID:
20339023
13.

Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?

Funke SA, Birkmann E, Willbold D.

Curr Alzheimer Res. 2009 Jun;6(3):285-9. Review.

PMID:
19519310
14.

Interference from heterophilic antibodies in amyloid-β oligomer ELISAs.

Sehlin D, Söllvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, Pettersson FE, Englund H.

J Alzheimers Dis. 2010;21(4):1295-301.

PMID:
21504116
15.

Tau monoclonal antibody generation based on humanized yeast models: impact on Tau oligomerization and diagnostics.

Rosseels J, Van den Brande J, Violet M, Jacobs D, Grognet P, Lopez J, Huvent I, Caldara M, Swinnen E, Papegaey A, Caillierez R, Buée-Scherrer V, Engelborghs S, Lippens G, Colin M, Buée L, Galas MC, Vanmechelen E, Winderickx J.

J Biol Chem. 2015 Feb 13;290(7):4059-74. doi: 10.1074/jbc.M114.627919. Epub 2014 Dec 24.

16.

Dissociation of β-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates β-amyloid-42 assembly.

Takamura A, Kawarabayashi T, Yokoseki T, Shibata M, Morishima-Kawashima M, Saito Y, Murayama S, Ihara Y, Abe K, Shoji M, Michikawa M, Matsubara E.

J Neurosci Res. 2011 Jun;89(6):815-21. doi: 10.1002/jnr.22615. Epub 2011 Mar 10.

PMID:
21394760
17.

Evidence that a synthetic amyloid-ß oligomer-binding peptide (ABP) targets amyloid-ß deposits in transgenic mouse brain and human Alzheimer's disease brain.

Chakravarthy B, Ito S, Atkinson T, Gaudet C, Ménard M, Brown L, Whitfield J.

Biochem Biophys Res Commun. 2014 Mar 14;445(3):656-60. doi: 10.1016/j.bbrc.2014.02.064. Epub 2014 Feb 22.

PMID:
24569075
18.

Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems.

Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Näslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L.

Mol Med. 2000 Apr;6(4):291-302.

19.

Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid.

Schuster J, Funke SA.

J Alzheimers Dis. 2016 May 7;53(1):53-67. doi: 10.3233/JAD-151029. Review.

PMID:
27163804
20.

Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Williams SM, Schulz P, Sierks MR.

Eur J Neurosci. 2016 Jan;43(1):3-16. doi: 10.1111/ejn.13056. Epub 2015 Oct 15.

Supplemental Content

Support Center